Comparative Study
doi: 10.1016/j.nucmedbio.2003.08.004.
Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice
Affiliations
- PMID: 15013487
- DOI: 10.1016/j.nucmedbio.2003.08.004
Item in Clipboard
Comparative Study
Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice
Nucl Med Biol.
2004 Feb.
Erratum in
- Nucl Med Biol. 2004 Oct;31(7):973
Abstract
The radiolanthanides (149)Pm, (166)Ho, and (177)Lu possess a range of half-lives and alpha(-) beta(-) energies for targeted radiotherapy of cancer. (149)Pm-, (166)Ho-, and (177)Lu-DOTA-biotin were pretargeted to LS174T colorectal tumors in nude mice with CC49 scFvSA antibody-streptavidin fusion protein. Tumor uptakes of (149)Pm (22.9% ID/g), (166)Ho (30.2% ID/g), and (177)Lu (35.4% ID/g) peaked at 1-4 h. Rapid blood disappearance was accompanied by urinary excretion of 59-66% ID within 1 h. Biodistributions of these agents show promise for pretargeted radioimmunotherapy of cancer.
Similar articles
-
Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.Bioconjug Chem. 2011 Dec 21;22(12):2444-52. doi: 10.1021/bc200258x. Epub 2011 Nov 14. Bioconjug Chem. 2011. PMID: 22053899
-
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.Clin Cancer Res. 2005 Nov 15;11(22):8180-5. doi: 10.1158/1078-0432.CCR-05-0607. Clin Cancer Res. 2005. PMID: 16299250
-
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.J Nucl Med. 2005 Apr;46(4):642-51. J Nucl Med. 2005. PMID: 15809487 Clinical Trial.
-
Pretargeted radioimmunotherapy.Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S57-9. doi: 10.1016/j.ijrobp.2006.04.058. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979441 Review.
-
Pretargeted radioimmunotherapy of cancer: progress step by step.J Nucl Med. 2003 Mar;44(3):400-11. J Nucl Med. 2003. PMID: 12621007 Review.
Cited by
-
Cutting edge rare earth radiometals: prospects for cancer theranostics.EJNMMI Radiopharm Chem. 2022 Aug 26;7(1):21. doi: 10.1186/s41181-022-00173-0. EJNMMI Radiopharm Chem. 2022. PMID: 36018527 Free PMC article. Review.
-
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.PLoS One. 2015 Mar 18;10(3):e0120561. doi: 10.1371/journal.pone.0120561. eCollection 2015. PLoS One. 2015. PMID: 25785845 Free PMC article.
-
Therapeutic Applications of Pretargeting.Pharmaceutics. 2019 Sep 1;11(9):434. doi: 10.3390/pharmaceutics11090434. Pharmaceutics. 2019. PMID: 31480515 Free PMC article. Review.
-
N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.Bioconjug Chem. 2013 Dec 18;24(12):2088-103. doi: 10.1021/bc400333m. Epub 2013 Nov 18. Bioconjug Chem. 2013. PMID: 24147780 Free PMC article.
-
Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):68-77. doi: 10.1007/s00259-006-0124-4. Epub 2006 Jun 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 16755333
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
